Hemangioma is the most common vascular disease of the skin in newborns. It is usually detected within 1 month after birth, then grows rapidly and stops growing until about 1 year of age. The damage depends on the growth site, size and tissue composition, and can cause deformities of the five senses, dysfunction and even life-threatening in severe cases. Previous foreign studies concluded that the incidence rate of Caucasian is 10%, which is significantly higher than that of Asian and African. However, in the past 10 years, the incidence rate in China has increased significantly, from 1% to 2% to 4% to 6%, which is an increase of 120% per 10,000 people, causing a great psychological and economic burden to parents of newborns. Studies on risk factors for hemangioma at home and abroad are mostly limited to birth history, such as prematurity, low birth weight, amniocentesis, etc. Few studies have explored diseases and medications during pregnancy. dickison et al. conducted a cohort study of perinatal factors in 1034 mothers of affected newborns and found that the incidence of hemangioma at 6 weeks was 2.6%. Female, prematurity (<37 weeks), low birth weight, and in vitro fertilization were high risk factors for the development of hemangioma. a prospective study by Haggstrom et al. showed that female, prematurity, and multiple pregnancies were significantly associated with the development of hemangioma; placenta praevia, preeclampsia, and advanced maternal age were more common in mothers of children with hemangioma. Assisted reproductive techniques such as IVF, ovulation promotion, and chorionic villus testing significantly increase the risk of hemangioma, with chorionic villus testing techniques in particular leading to a more than 1-fold increase in the incidence of hemangioma. In recent years, hypoxia during pregnancy has also been considered as a possible risk factor. In a retrospective study conducted by Wang Lin et al. at the Department of Preventive Health Care, China-Japan Friendship Hospital, Ministry of Health, on mothers of newborns born from January 2010 to June 2011 in the large community under their jurisdiction, a total of 953 valid questionnaires were obtained and 34 cases of hemangioma were found, with an incidence rate of 3.6%. A comparison of the maternal exposure factors of the 34 mothers of affected children with those of normal newborn mothers revealed that maternal age >35 years, child sex, progesterone and overdose of multivitamins were the maternal exposure factors significantly associated with the occurrence of hemangioma. Progesterone has been used for decades as a fetal preservation drug for the treatment of preterm and habitual abortions, and its main role is to maintain pregnancy in the presence of luteal insufficiency. Progesterone is currently used clinically as a natural preparation, usually 10-20 mg/d intramuscularly or orally, until the 12th week of pregnancy. Its main side effects are dizziness, headache, nausea, depression, etc. There is no teratogenic effect of artificial progesterone on the fetus. Progesterone may be a factor associated with the development of hemangioma, however, the general reasons for progesterone use in pregnant women are early pregnancy bleeding, fetal dysplasia, and a tendency to preterm abortion. Therefore, the possibility of adverse genetic, environmental and maternal factors contributing to the development of hemangioma cannot be ruled out. The relationship between progesterone and the occurrence of hemangioma needs to be confirmed by further studies.